Family-Based Support Program to Reduce Psychotic-Like Experiences in Young People at Risk of Schizophrenia
Tests a brief family program in young people with a family history of schizophrenia.
Plain-language title generated from the registry record
Registry title: Developing Biomarker-Supported Schizophrenia Spectrum Disorder (SSD) Prevention
Key facts
- Where
- Houston, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 9 and 26 years old?
Source: NCT07743645, who can take part
Where in United States
- The University of Texas Health Science Center at HoustonHouston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The University of Texas Health Science Center, Houston
- Trial code
- NCT07743645
- Record updated
- 30 October 2026
- Original description
The purpose of this study is to compare the effect of a brief family-based psychosocial intervention that addresses modifiable SSD risk factors on persistent and distressing psychotic-like experiences in children and young adults with a family history of SSD and high versus low baseline SSD-like brain patternsRead full original descriptionShow less
Developing Biomarker-Supported SSD Prevention
The purpose of this study is to compare the effect of a brief family-based psychosocial intervention that addresses modifiable SSD risk factors on persistent and distressing psychotic-like experiences in children and young adults with a family history of SSD and high versus low baseline SSD-like brain patterns
Inclusion: Family history of SSD (defined as first-degree (e.g., a parent or a sibling), second-degree (e.g., an uncle or a grandparent), or other combinations of biological relatives in the family have or likely have a diagnosis of SSD or other closely related severe mental illnesses equivalent to at least 25% of genetic sharing) per medical record review and/or parent/legal guardian/self report and confirmed by a structured interview; screening positive for two or more risk factors targeted by the intervention; aged ≥ 9 and <26 years of birthday; Participants and parent(s)/legal guardian(s)/other family member(s) agree to participate; psychiatrically stable and have no major changes in antidepressant, stimulant, or antipsychotic medication in the past 4 weeks.
Exclusion: current drug or alcohol use that impacts functioning and study engagement; Current or past history of psychotic disorders or clinical high risk for psychosis (CHR-p) per study interview; Current or past antipsychotic medication use to specifically treat a psychotic disorder; major medical and neurological conditions; moderate to severe intellectual disabilities or mild intellectual disabilities but expected to have difficulty completing the study assessments; Not able to give assent, permission, or consent; Not able to undergo MRI.